Generation of Human-Induced Pluripotent Stem Cells from Peripheral Blood Mononuclear Cells using Small-Molecule Compound VC6TFZ

by Aprihati Aprihati
Generation of Human-Induced Pluripotent Stem Cells from Peripheral Blood Mononuclear Cells using Small-Molecule Compound VC6TFZ

Aprahati Aprahati**, B. S. Pkir, Andrianj Andrianto

Department of Cardiology and Vascular Medicine, Arlanaga University, Surabaya, Indonesia

Abstract

BACKGROUND: Induced pluripotent stem cells (iPSCs) were generated from somatic cells through reprogramming process. Peripheral blood mononuclear cells (PBMCs) were an attractive source cells due to the ease of accessibility, need minimal invasive procedure, and can be stored frozen. Small-molecule compound VC6TFZ has been successfully reprogrammed into iPSCs from mouse fibroblast, but it has not been proven in human.

AIM: This study aims to determine whether the small-molecule compound VC6TFZ can induce pluripotency of PBMC to generate iPSCs.

METHODS: Mononuclear cells were isolated from peripheral venous blood using centrifugation gradient density method. Mononuclear cells were cultured for 6 days in expansion medium and 48 h using hanging drop method. Pluripotency induction process using small-molecule compound VC6TFZ was done in 14 days then the medium changed to cultures for 7 days. Identification of iPSCs based on colony morphology and expression of pluripotency marker OCT4 and SOX2.

RESULTS: Colonies appeared on day 9 of reprogramming process. These colonies had round, large, and cobblestone morphology like embryonic stem cell. These colonies had positive expression of pluripotency markers OCT4 and SOX2. All experimental groups had significantly higher expression of OCT4 and SOX2 than control group.

CONCLUSION: Small-molecule compound VC6TFZ could induce pluripotency of human PBMC to generate iPSCs.

Introduction

Pluripotent stem cells play an important role in regenerative medicine due to their ability to differentiate into all cell types and unlimited self-renewal. The common source of pluripotent stem cells was embryonic stem cells (ESCs) which are generated from inner cell mass of embryo at blastocyst stage. The use of ESCs was controversial due to some ethical issue related to embryo destruction, risk of immune rejection, and limited source due to embryo origin. Induced pluripotent stem cells (iPSCs) have been an alternative source of pluripotent stem cells which tackled the ethical issue because it originates from somatic cells. Potential application of iPSCs such as provides cells for cell transplantation therapy, disease modeling, and drug screening [1].

iPSCs were generated from somatic cells by reprogramming process using various reprogramming factors. Skin fibroblast cells were the first source cells and still being the most frequently used [2], [3]. Skin biopsy procedures were uncomfortable, leave scar tissue, and require a long time for fibroblast cell expansion, limiting the use of fibroblasts as a source of iPSCs. Other source cells were keratinocytes, mesenchymal stem cells from adipose tissue, cord blood cells, and peripheral blood cells. Peripheral blood cells were one of the attractive sources of iPSCs because easy to collect, minimally invasive, and can be stored in a frozen form [4].

Blood cells were continuously replaced by stem cells in bone marrow, made these cells less susceptible to environment-associated point mutation than skin which exposed to ultraviolet light. The quality of iPSCs derived from peripheral blood mononuclear cell (PBMCN) and fibroblasts was equivalent and difficult to distinguish from ESCs. iPSCs derived from PBMCN were comparable to ESCs in terms of morphology, expression of surface antigens, activation of endogenous pluripotent genes, DNA methylation, and differentiation abilities [5].

Since its discovery, iPSCs were generated through transduction of exogenous transcription factors OCT4, SOX2, KLF4, and c-Myc (OSKM) into the nucleus of somatic cells transferred using retroviruses [2], [3]. The reprogramming process which used exogenous transcription factors with integrative systems associated with low efficiency, risk of mutagenesis, and tumorigenesis thereby limiting their use for clinical
applications. Various approaches were made to improve the efficiency and safety of iPSCs for clinical applications, one of the strategies was the use of small molecules [6].

At present, small molecules have an important role in reprogramming. Small molecules that worked on signaling pathways, epigenetic modifications, and metabolic processes had been widely used to improve reprogramming efficiency using exogenous transcription factors. The combination of several small molecules could induce pluripotency despite without exogenous transcription factors [7]. Small molecules were cell permeable and non-immunogenic. Small molecules were more cost efficient, easy to manufacture, can be stored, and standardized. Another advantage was that it did not involve genetic manipulation so it was safer, had fast biological effect, reversible, the effect can be controlled by modifying dosage and combinations [8].

VC6TFZ was a combination of small molecules consisting of valproic acid (VPA), CHIR990210 (CHIR), 616452 (Repsox), tranylcypromine, forskolin, 3-deazaneplanocin (DZNep), and 4-((E)-2-(5,6,7,8-Tetrahydro-5,8,8-trimethyl-2-naphthalenyl)-1-propenyl)benzoic acid, or also called TTNPB. The combination of these small molecules could induce pluripotency in mouse embryonal fibroblasts (MEFs) with higher efficiency than the Yamanaka protocol that used exogenous transcription factors (0.02% vs. 0.001–0.01%) [9]. This study was the first study aimed to prove whether the small-molecule compound VC6TFZ could induce pluripotency in human PBMCN.

Methods

This study was a post-test control group only design in vitro study. This study protocol, as shown in Figure 1, consisted of several steps including PBMCN isolation, PBMCN culture, pluripotency induction using small molecules, and iPSCs identification. Blood samples were derived from a 31-year-old female volunteer.

![Figure 1: Study protocol](image)

**PBMCNs Isolation**

Blood was collected into heparin-coated tubes. Collected blood was diluted with 5 cc phosphate-buffered saline (PBS) and centrifuged through a Ficoll gradient for 30 min at 1600 × g. PBMCNs were collected and transferred to a new tube and add 10 cc PBS, centrifuged for 5 min at 2000 × g. Supernatant was aspirated and resuspend at 10 cc PBS.

**Peripheral blood mononuclear culture**

PBMCNs were cultured at Roswell Park Memorial Institute (RPMI) medium enriched with L-glutamine 1 mL/100 mL, ITS 1 mL/100 mL, FGF 5 ng/mL, ascorbic acid 5 mg/100 mL, GMCSF 50 uL/100 mL, and dexamethasone 100 uL/100 mL. Mononuclear cells were cultured for 6 days, and medium was changed every 2 days. After 6 days culture at RPMI medium, PBMCNs were cultured using hanging drop method for 2 days. Hanging drop culture was done by dropping the cell suspension using tip of the pipette at 5 cm Petri dish cover. The cover dish then reversed, continued with incubating cells at 37°C CO2 for 48 hours without adding medium.

**Pluripotency induction using small-molecule compound VC6TFZ**

Three drops of mononuclear cell suspension were transferred to M-24 well plate pre-coated with vitronectin overnight and feeder cells. Feeder cells were made from mitosis-inactivated rabbit adipose mesenchymal cells using mitomycin-C 2 μg/mL for 30 min. Add ReproTesR medium which contained small-molecule VC6TF. At day 7, DZNep was added. Cells were exposed to small molecules for 14 days. The medium was changed every 4 days. On day 14, VC6TFZ was changed to 2i medium (PD0325901 and CHIR) for 7 days.

The cells were grouped into four groups. Group 1 (P1) was the control group, which was not exposed to small molecule. Group 2 (P2) was the experimental groups which exposed to small molecule dosage VPA 0.5 mM, CHIR 5 uM, 614652 2 uM, tranylcypromine 2.5 uM, FSK 20 uM, DZNep 20 nM, and TTNPB 5 uM. Group 3 (P3) was the experimental groups which exposed to small-molecule dosage VPA 0.75 mM, CHIR 10 uM, 614652 7.5 uM, tranylcypromine 5 uM, FSK 40 uM, DZNep 50 nM, and TTNPB 5 uM. Group 4 (P4) was the experimental groups which exposed to small-molecule VPA 1 mM, CHIR 20 uM, 614652 10 uM, tranylcypromine 10 uM, FSK 60 uM, DZNep 100 nM, and TTNPB 5 uM.

**iPSCs identification**

Identification of iPSCs was done by morphology identification and expression of pluripotency markers (SOX2 and OCT4). iPSC colonies had large characteristics, tight and clear border, and cobble stone-like appearance. In iPSC colonies, cells had a small size with a large ratio of cytoplasmic nuclei.
**Immunohistochemical staining**

Cells were fixed with methanol for 10 min, then washed with cold PBS 2 times. The cells were then stabilized with 0.25% Triton X-100 on PBS for 10 min at room temperature. The cells were washed with PBS 3 times for 5 min. Cells were incubated with 1% bovine serum albumin (BSA) in phosphate-buffered saline with Tween (PBST) for 30 min. Cells were then incubated in antibody solution (OCT4 and SOX2) in 1% BSA in PBST in humidified chamber for 1 h at room temperature or overnight at 4°C. The procedure continued with washing the cells for 5 minutes with PBS, repeated for 3 times. The cell was then incubated with the Alexa Fluor 488 goat anti-mouse IgG secondary antibody. Fluorescent signal is then viewed under a microscope.

**Statistical analysis**

Collected data were coded, tabulated, and statistically analyzed using the SPSS version 24. OCT4 and SOX2 expressions will be presented means SD. Data normality test was done using Kolmogorov-Smirnov test. Differences in OCT4 expression and SOX2 expression between the four groups will be analyzed by one-way ANOVA test if the data were normally distributed and Kruskal-Wallis if the data were not normally distributed. The difference was said to be significant if p < 0.05.

**Results**

iPSCs like colony were appeared at day 9 after cells were exposed to small molecule. Colonies had large and round morphology with cobbled stone-like appearance (Figure 2).

![Figure 2: Changed of colonies morphology at day 0–day 21](image_url)

All colonies were expressed pluriptotest markers. OCT4 expression was found in all treatment groups with the strongest expression in P3 group. Cells that had strong expressions of OCT4 will glow bright green (Figure 3), the degree of luminance will be measured quantitatively using ImageJ software. Significant differences were found between the P3 and P4 groups with the control group (p = 0.000, p = 0.022), whereas between the P2 group and the control, there was no significant difference (p = 0.116) as shown in Table 1.

| Control group | V20/AT3 experimental group mean ± SD | OCT4 | p       |
|---------------|--------------------------------------|------|---------|
| 10.20 ± 6.99  | P1: 49.93 ± 10.49                     | 0.121|         |
| 10.12 ± 6.70  | P2: 36.15 ± 5.73                      | 0.000|         |
| 10.14 ± 6.58  | P3: 16.85 ± 8.74                      | 0.032|         |

**Table 1: Comparison of OCT4 expression between groups**

All colonies also expressed SOX2 markers (Figure 4).

![Figure 4: SOX2 expression in each group](image_url)

The mean SOX2 expression was stronger in all treatment groups compared to the control group, with the strongest expression found in the P3 group. There was a significant difference between the control group.
with P3 and P4 (p = 0.028; p = 0.006), but there was no significant difference between the control group with P2 (p = 0.116) as shown in Table 2.

Table 2: Comparison of SOX2 expression between groups

| Control group | V6FTZ experimental group | n=5 | p | SOX2 |
|---------------|--------------------------|-----|---|------|
|               |                          |     |   | 0.166 |
| P2: 142.41 ± 12.542 |                          | 5   |   | 0.028 |
| P3: 277.59 ± 12.738 |                          | 5   |   | 0.028 |
| P4: 171.75 ± 61.54439 |                          | 5   |   | 0.005 |

Discussion

iPSCs were generated from somatic cells through the reprogramming process. These stem cells had the ability to differentiate into all cell types and unlimited self-renewal abilities. This property made these cells had potential as cell sources for cell transplantation therapy, disease modeling, and drug screening [10]. The first and most widely used cell source for the generation of iPSCs was skin fibroblasts [4], [8]. This study used PBMNC as a source for iPSCs due to their ease of accessibility, minimally invasive, and less susceptible to point mutation [5]. Many research had been done to generate iPSCs from PBMNC, where these iPSCs had similar quality as iPSCs derived from fibroblasts [11], [12], [13]. The previous studies used Sendai virus, Lentivirus, and episomal vector for pluripotency induction in PBMNC [11], [12], [13], [14]. This study was the first study that used small molecules to induce human PBMNC pluripotency.

In this study, we found that small-molecule compound VC6FTZ could induce pluripotency in human PBMNC. It was proven by the formation of colonies that resembled iPSCs morphology and the expression of pluripotency markers (OCT4 and SOX2). In this study, we found a colony that began to appear on the 3rd day of induction and increasing largely on day 9. The colonies had round morphology, cobble stone like, and clear edges. This colonies morphology resembles iPSCs as described in the guidelines and techniques for the generation of iPSCs [15].

The colonies in this study express pluripotency markers, OCT4 and SOX2. The expressions of each marker were analyzed quantitatively using ImageJ software, which obtained higher expressions in all treatment groups compared to the control group. Statistically, there were significant differences between the control group and the P3 and P4 groups in OCT4 expression (p = 0.000; p = 0.002) and SOX2 (p = 0.028; p = 0.006). This indicates the most optimal expression of OCT4 and SOX2 at small-molecule P3 and P4. This indicates that the effect of small molecule on the success of reprogramming was dose dependent [9], [16]. The key for reprogramming successful with small molecules was the concentration and combination of small molecules. Small molecules could be cytotoxic at certain concentrations so that at higher doses, the reprogramming efficiency was sometimes even lower [16].

The protocol we used in this study was different from the previous studies, where the induction was done in only 21 days, faster than the Hou et al. In Hou's study, GFP-positive colonies began to appear around day 10–12, while in this study, the colonies appeared earlier at day 6. This was likely due to the optimized culture method and the hanging drop culture method. Optimization of PBMNC culture plays an important role in the reprogramming process. In this study, we cultured PBMNC for 6 days in an expansion medium. During culture period, the longer duration the more number of dead cells, but the number of living cells remains constant, so the optimal duration of culture time was needed. This 6-day duration was based on research conducted by Gu et al. where this study showed that the 6-day culture time shows the number of colonies that most expressed TRA 1-60 and AP compared to days 4.8 or 10 [17].

Hanging drop culture method allows the formation of colonies through cell aggregation induced by gravity [18]. The accumulation of cells in the drop allows the formation of spheroidal colonies. Spheroid colonies that were formed can produce extracellular matrices and environments that resemble living tissue. Inside the drop cells adhere to each other by holding on the resulting matrix. Inter cell interactions and interactions between cells and extracellular matrix were better with this method [19], [20]. This method also allows more efficient diffusion of growth factors and metabolic waste disposal [21].

In this research, small-molecule compound VC6FTZ was combination of VPA, CHIR, 616452, tranylcypromine, FSK, and DZnap. The VC6FTZ combination was first discovered by Hou et al. after screening 10,000 small molecules. Hou has succeeded in generating iPSCs derived from MEF using VC6FTZ without any exogenous transcription factors [9].

The CHIR, FSK, and 616452 (Repsox) components induce the expression of SalI4 and SOX2 pluripotent genes in the early phase of the cellular reprogramming process. Concomitant overexpression between SalI4 and SOX2 can activate OCT4 promoter-driven luciferase reporter so that it is sufficient to replace C6F for OCT4 induction. Expression of OCT4 increased significantly with the addition of DZnap. DZnap was important to stimulate OCT4 expression, but not other pluripotent genes. As a S-adenosylhomocysteine hydrolase (SAH) hydrolase inhibitor, DZnap increased the concentration ratio of SAH and S-adenosylmethionine (SAM), thereby reducing the SAM-dependent cellular methylation process. The role of DZnap in OCT4 activation occurs through decreased DNA and H3K9 methylation in the OCT4 promoter region. OCT4 and SOX2 then activate other pluripotent genes such as Nanog. SOX2, OCT4, and Nanog activated each other to form a pluripotency circuit that maintains the pluripotent nature of a cell.
OCT4 expression expressed in somatic cells through various epigenetic modifications, opened with a chemical cellular reprogramming process using the D2Nep epigenetic modulator, and stimulated by G6F-induced expression Sox2-Sall4 [9].

One of the challenges in reprogramming PBMNC was that these cells had non-adherent nature [13]. To overcome this problem, we coated the well walls using vitronectin and feeder cells that enable the PBMNC attachment on the well. This attachment was important to avoid cell lost during medium replacement. Previously, we only used vitronectin to coat the well, but the cells were still not adherent so we decided to make feeder cells. This feeder cell produces stemness-supporting factors that prevent spontaneous differentiation. This feeder cell produced adhesion molecules and extracellular matrix that increases attachment of iPSCs which supports growth and survival [22], [23].

Other feeder cells types used for in ESC/iPSCs production such as MEFs, STO cells, and SNL 76/7 cells. The most widely used was MEF proliferation-inactivated using mitomycin-C or gamma X-ray. Inactivation of mitosis or MEF irradiation stimulated the expression of several proteins such as Wnt-3 that contributed to molecular mechanisms in maintaining pluripotency. MEFs produced various proteins such as transforming growth factor beta 1, activin A, bone morphogenetic protein-4, and plectrophin (heparin-binding growth factor). Vitronectin was an extracellular matrix protein that was rich in peptide arginine-glycine-aspartate (RGD) needed for integrin-mediated cell adhesion and growth through cellular pathway activation. Vitronectin also supports self-renewal and pluripotency from ESC [22]. In this study, we used rabbit adipose mesenchymal cells which mitosis-inactivated using 2 µg/mL mitomycin-C for 30 min. This dose was smaller than the dose used in the literature for MEFs which was 10 μg/mL [23], [24].

Conclusion

This was the first study that showed small-molecule compound V6GTFZ could induce pluripotency in human PBMNC. Further research was needed to analyze molecular profile, differentiation, and self-renewal ability of these cells. For clinical application, the safety profile related to the risk of tumorigenesis and genetic instability also needed further investigation.

Acknowledgments

The authors would like to thank to Rizka Amalia, MD for her contribution in this research.

References

1. Singh V, Kates M, Kumar N, Saini A, Chandra R. Induced pluripotent stem cells. Applications in regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol. 2015;3:1-16. https://doi.org/10.3389/fcell.2015.00002 PMID:25899255
2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76. https://doi.org/10.1016/j.cell.2006.07.024 PMID:16904174
3. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-72. https://doi.org/10.1016/j.cell.2007.11.019 PMID:18035408
4. Raab S, Klingenstein M, Liebau S, Linta L. A comparative view on human somatic cell sources for iPSC generation. Stem Cells Int. 2014;2014:768391. https://doi.org/10.1155/2014/768391
5. Loh YH, Hartung O, Li H, Guo C, Sahatte JM, Manos PD, et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell. 2010;7(1):15-9. PMID:20621044
6. Atwood S, Edel M. IPS-cell technology and the problem of genetic instability can it ever be safe for clinical use? J Clin Med. 2019;8(3):288. https://doi.org/10.3390/jcm8030288 PMID:30832421
7. Baranek M, Beller A, Naskre MZ, Stobiack M, Markiewicz WT, Bartczaszewski J. Effect of small molecules on cell reprogramming. Mol Biosyst. 2017;13(2):277-313. https://doi.org/10.1039/c6mb0099k PMID:27916059
8. Qin H, Zhao A, Fu X. Small molecules for reprogramming and transdifferentiation. Cell Mol Life Sci. 2017;74(19):3553-75. https://doi.org/10.1007/s00018-017-2586-x PMID:28698392
9. Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science. 2013;341(6146):651-4. https://doi.org/10.1126/science.1239278 PMID:23866920
10. Gomes KM, Costa IG, Santos JF, Dourado PM, Forni MF, Ferreira JC. Induced pluripotent stem cells reprogramming: Epigenetics and applications in the regenerative medicine. Rev Assoc Med Bras. 2017;63(2):189-96. https://doi.org/10.1590/1806-9282.63.02.180 PMID:28355380
11. Kim Y, Rim Y, Yi H, Park N, Park SH, Ju JH. The generation of human induced pluripotent stem cells from blood cells: An efficient protocol using serial plating of reprogrammed cells by centrifugation. Stem Cells Int. 2016;2016:1329459. https://doi.org/10.1155/2016/1329459 PMID:27576041
12. Wen W, Zhang JP, Chen W, Arakaki C, Li X, Baylink D, et al. Generation of integration-free induced pluripotent stem cells from human peripheral blood mononuclear cells using epiblastic vectors. J Vis Exp. 2017;2017(119):1-7. https://doi.org/10.3791/55091 PMID:28117800
13. Ye H, Wang Q. Efficient generation of non-integration and feeder-free induced pluripotent stem cells from human peripheral blood cells by sendai virus. Cell Physiol Biochem.
14. Su RJ, Neises A, Zhang X. Generation of iPSCs from human peripheral blood mononuclear cells using episomal vectors. Methods Mol Biol. 2016;1357:57-69. https://doi.org/10.1007/9781-2014-136
PMID:25403468

15. Maherell N, Hochfeldinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell. 2008;3(6):606-605. https://doi.org/10.1016/j.stem.2008.11.008
PMID:19041778

16. Zhou J, Sun J. A revolution in reprogramming: Small molecules. Curr Mol Med. 2019;19(2):77-90.
PMID:30914022

17. Gu H, Huang X, Xu J, Song L, Liu S, Zhang XB, et al. Optimizing the method for generation of integration-free induced pluripotent stem cells from human peripheral blood. Stem Cell Res Ther. 2018;9(1):1-10. https://doi.org/10.1186/s13287-018-0908-z
PMID:29907164

18. Runzlanlert S. Embryoid body formation from embryonic and induced pluripotent stem cells: Benefits of bioreactors. World J Stem Cells. 2009;1(1):11-21. https://doi.org/10.4262/wjcc. v1.11.11
PMID:21607103

19. Fity R. A simple hanging drop cell culture protocol for generation of 3D spheroids. J Vis Exp. 2011;5(1):2-6. https://doi.org/10.3791/2720
PMID:21567162

20. Antisanto RD, Septiana WL, Jusuf AA, Baisa A, Pawitan JA, Fasha I. Perbandingan kultur 2D dan 3D dengan metode hanging drop untuk menghasilkan micro-environment yang lebih relevan secara klinis. J.Kedokt Indonesia. 2017;5(2):121-6. https://doi.org/10.23966/jki.5.7701

21. Jitry SJ, Malindea ST, Nwasa M. 2D and 3D Cell Culture in Drug Discovery. London: Intech; 2016.

22. Yu G, Kamano Y, Wang F, Okawa H, Hirofumi Y, Egusa H. Feeder cell sources and feeder-free methods for human iPS cell culture. In: Interface Oral Health Science. Berlin: Springer; 2015. p. 351. https://doi.org/10.1007/978-4-431-55152-8_12

23. Li P, Wang Z, Zhan L, He X, Chi G, Lu S, et al. Efficient feeder cells preparation system for large-scale preparation and application of induced pluripotent stem cells. Sci Rep. 2017;7(1):1-15. https://doi.org/10.1038/s41598-017-10428-5
PMID:28947775

24. Corner DA. Mouse embryo fibroblast (MEF) feeder. Curr Protoc Mol Biol. 2002;25(2):1-23.
PMID:18265203
Generation of Human-Induced Pluripotent Stem Cells from Peripheral Blood Mononuclear Cells using Small-Molecule Compound VC6TFZ

**ORIGINALITY REPORT**

| SIMILARITY INDEX | INTERNET SOURCES | PUBLICATIONS | STUDENT PAPERS |
|------------------|------------------|--------------|----------------|
| 16%              | 11%              | 13%          | 0%             |

**PRIMARY SOURCES**

1. Youngkyun Kim, Yeri Alice Rim, Hyoju Yi, Narae Park, Sung-Hwan Park, Ji Hyeon Ju. "The Generation of Human Induced Pluripotent Stem Cells from Blood Cells: An Efficient Protocol Using Serial Plating of Reprogrammed Cells by Centrifugation", Stem Cells International, 2016
2. Stefanie Raab, Moritz Klingenstein, Anna Möller, Anett Illing et al. "Reprogramming to pluripotency does not require transition through a primitive streak-like state", Scientific Reports, 2017
3. tessera.spandidos-publications.com
4. www.jlr.org
5. hstalks.com
J. Waller, L. A. V. Marlow, J. Wardle. "The association between knowledge of HPV and feelings of stigma, shame and anxiety", Sexually Transmitted Infections, 2006.
"The prevalence of depressive symptoms, anxiety symptoms and sleep disturbance in higher education students during the COVID-19 pandemic: A systematic review and meta-analysis", Psychiatry Research, 2021

Meera Nair, Sardul Singh Sandhu, Anil Kumar Sharma. "Induced Pluripotent Stem Cell Technology: A Paradigm Shift in Medical Science for Drug Screening and Disease Modeling", Current Medicinal Chemistry, 2017

Yujing Wang, Yuqin Gao, Yang Xun. "Work Engagement and Associated Factors Among Dental Nurses in China", Research Square, 2021

ejnpn.springeropen.com

josr-online.biomedcentral.com

core.ac.uk

iopscience.iop.org

journals.plos.org
Abdullah Aslan, Muhammed Ismail Can, Ozlem Gok, Seda Beyaz, Gozde Parlak, Ibrahim Hanifi Ozercan. "The inducing of caspase and bcl-2 pathway with royal jelly decreases the muscle tissue damage exposed with fluoride in rats", Research Square Platform LLC, 2021

Hanife Gündoğdu Köseoğlu, Burçin Cansu Bozca, Cumhur İbrahim Bassorgun, Ramazan Sarı et al. "The Role of Insulin-like Growth Factor in Acrochordon Etiopathology", Research Square, 2019

Pengdong Li, Shichao Wang, Lixiang Zhan, Xia He, Guangfan Chi, Shuang Lv, Ziran Xu, Yuhan Xia, Shuzhi Teng, Lisha Li, Yulin Li. "Efficient feeder cells preparation system for large-scale preparation and application of induced pluripotent stem cells", Scientific Reports, 2017
Su, Ruijun Jeanna, Amanda Neises, and Xiao-Bing Zhang. "Generation of iPS Cells from Human Peripheral Blood Mononuclear Cells Using Episomal Vectors", Methods in Molecular Biology, 2014.

Dan Xu, Zaida Alipio, Louis M. Fink, Dorothy M. Adcock, Jianchang Yang, David C. Ward, Yupo Ma. "Phenotypic correction of murine hemophilia A using an iPS cell-based therapy", Proceedings of the National Academy of Sciences, 2009

Pim R. R. van Gorp, Serge A. Trines, Daniël A. Pijnappels, Antoine A. F. de Vries. "Multicellular In vitro Models of Cardiac Arrhythmias: Focus on Atrial Fibrillation", Frontiers in Cardiovascular Medicine, 2020

Ye, Junqing, Jian Ge, Xu Zhang, Lin Cheng, Zhengyuan Zhang, Shan He, Yuping Wang, Hua Lin, Weifeng Yang, Junfang Liu, Yang Zhao, and Hongkui Deng. "Pluripotent stem cells induced from mouse neural stem cells and small intestinal epithelial cells by small molecule compounds", Cell Research, 2015.
| Publication |
|-------------|
| 32 | www.mdpi.com | Internet Source |
| 33 | www.tandfonline.com | Internet Source |
| 34 | M. Pagano, S. Naviglio, A. Spina, E. Chiosi, G. Castoria, M. Romano, A. Sorrentino, F. Illiano, G. Illiano. "Differentiation of H9c2 cardiomyoblasts: The role of adenylate cyclase system", Journal of Cellular Physiology, 2004 |
| 35 | Riham Fliefel, Michael Ehrenfeld, Sven Otto. "Induced Pluripotent Stem Cells (iPSCs) as a new source of bone in Reconstructive Surgery: A Systematic Review and Meta-analysis of Preclinical Studies.", Journal of Tissue Engineering and Regenerative Medicine, 2018 |
| 36 | Xiugong Gao, Jeffrey J. Yourick, Robert L. Sprando. "Chapter 372 Generation of Human Induced Pluripotent Stem Cells Using Endothelial Progenitor Cells Derived from Umbilical Cord Blood and Adult Peripheral Blood", Springer Science and Business Media LLC, 2021 |
| PAGE 1 | | |
|---|---|---|
| PAGE 2 | | |
| PAGE 3 | | |
| PAGE 4 | | |
| PAGE 5 | | |
| PAGE 6 | | |

Generation of Human-Induced Pluripotent Stem Cells from Peripheral Blood Mononuclear Cells using Small-Molecule Compound VC6TFZ

**GRADEMARK REPORT**

| FINAL GRADE | GENERAL COMMENTS |
|---|---|
| /100 | Instructor |